CD8A and neoplasm: Chen et al. developed APOC2-K70-la antibody and demonstrated that it considerably reduced tumor size, increased tumor-infiltrating CD8+ T cells, and markedly enhanced immunotherapeutic efficacy when co-administered with anti-PD-1 mAb (Chen J. et al., 2024).